Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kaixinren And Nikko Cordial Securities Sign Agreement

This article was originally published in PharmAsia News

Executive Summary

After receiving 100 million yuan in funding from Nikko Antfactory at the beginning of this year, Kaixinren chain drugstore has signed an agreement based on adjustable evaluation with Nikko Cordial Securities, which controls Nikko Antfactory. Nikko Antfactory will continue to pump $30 million yuan to $50 million yuan into Kaixinren within the next two years, with a goal of Kaixinren getting listed by 2010. Kaixinren has set out a 10-year strategy that includes opening 1,000 shops in three years, then gradually building up to 1,800 stores to become a world-class pharmaceutical corporation. It also aims to hit sales of 10 billion yuan within five to ten years. (Click here for more - Chinese Language)

You may also be interested in...

Sun Adds To Criticism Over Medicare 505(b)(2) Policy

Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.

Bluebird’s Eli-Cel Gene Therapy Among Myriad New Drugs Seeking EU Approval

An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.

Peptomyc Battles Cancer R&D Conventions

Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts